Fundraising Fox
/Companies
Sign in

TYRA Biosciences

NASDAQ: TYRA

Carlsbad, US · Delaware corporation · 115 employees on LinkedIn · 6 known investors

Find your way into TYRA Biosciences

Each arrow is one introduction. Sign up to fill in the first one.

55 people can intro you to Alan

Ask Annie Mitsak to introduce you to Alan Fuhrman

You →Annie · together at Checkmate Pharmaceuticals →Alan

Sign up to find every way you can get introduced to TYRA Biosciences

  • Your email: who you already know at TYRA Biosciences, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the TYRA Biosciences team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers. The company operates in the biotech/pharmaceutical drug development space.

BiotechHealthtech

Founders & leadership

TH
Todd Harris, Ph.D.Founder
HT
Hiroomi Tada, M.D., Ph.D.Executive
DBDaniel Bensen
Daniel BensenChief Discovery Officer and Co-Founder
AF
Alan FuhrmanChief Financial OfficerAlan Fuhrman has held executive and board positions for over 25 years in life sciences and technology, including roles as President or CFO at biotech firms where he oversaw public offerings and M&A transactions, and has served as audit chair and committee member at multiple public companies.
THTodd Harris
Todd HarrisFounder & CEODirector, Executive Officer at Sienna Biopharmaceuticals
BABhavesh Ashar
Bhavesh AsharChief Operating Officer
DWDouglas Warner
Douglas WarnerChief Medical Officer

Board

RM
Robert MoreBoard directorManaging Director at Alta Partners
NK
Nina KjellsonBoard Member2020–2025Investor at Canaan Partners
MM
Melissa McCracken, Ph.D.Board director
SS
Sid Subramony, Ph.D.Board director
JS
Jake Simson, Ph.D.Board director

Investors · 6

BioBritlisted by BioBritLa Jolla
Nextech Investlisted by Nextech InvestZurich · $648K – $3.2M

How we know: a partner's Signal profile · Not right? Tell us

Canaan PartnersreportedStamford · $500K – $20Mvia Nina Kjellson · board

How we know: the S-1 prospectus · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us

NEXTECH ONCOLOGY SCSPreportedSenningerberg

How we know: the S-1 prospectus · Not right? Tell us

RA CapitalreportedBoston

How we know: the S-1 prospectus · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$200M disclosed across 1 round · 2024

▶$200MraisedFeb 2024 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert MoreDirector
  • Hiroomi Tada, M.D., Ph.D.Executive Officer
  • Isan Chen, M.D.Director
  • Daniel BensenExecutive Officer
  • Nina KjellsonDirector
  • Alan FuhrmanExecutive Officer
  • Rehan VerjeeDirector
  • Melissa McCracken, Ph.D.Director
  • Sid Subramony, Ph.D.Director
  • Gilla Kaplan, Ph.D.Director
  • Jake Simson, Ph.D.Director
  • Todd Harris, Ph.D.Executive Officer, Director
Offering amount
$200M
Amount sold
$200M
First sale
Feb 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$654.6Mvaluation at IPOSep 2021 · $16.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Related companies · 3

Atara BiotherapeuticsAtara Biotherapeutics develops allogeneic T-cell immunotherapies using its proprietary EBV T-cell platform to harness the immune system for treating disease. The company focuses on next-generation cell-based therapies designed for patients worldwide.
TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

Companies working in the same space as TYRA Biosciences.

Frequently asked questions

What does TYRA Biosciences do?
Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers. The company operates in the biotech/pharmaceutical drug development space.
Who founded TYRA Biosciences?
TYRA Biosciences was founded by Todd Harris, Ph.D..
Who are TYRA Biosciences's investors?
TYRA Biosciences's investors include Alta Partners, BioBrit, Nextech Invest, Canaan Partners, NEXTECH ONCOLOGY SCSP, RA Capital.
How much funding has TYRA Biosciences raised?
TYRA Biosciences has disclosed $200M raised across 1 round.
Where is TYRA Biosciences headquartered?
TYRA Biosciences is headquartered in Carlsbad, US.